2.50
Hdl Handle:
http://hdl.handle.net/10755/157670
Type:
Presentation
Title:
Diabetes, Hypertension and African American Females With Schizophrenia
Abstract:
Diabetes, Hypertension and African American Females With Schizophrenia
Conference Sponsor:Western Institute of Nursing
Conference Year:2009
Author:Weber, Mary T., PhD, APRN, PMHNP-BC
P.I. Institution Name:University of Colorado Denver, College of Nursing
Title:Associate Professor
Contact Address:13120 East 19th Ave. C288-18; Room 4234, Aurora, CO, 80045, USA
Contact Telephone:303-724-2949
Aim: 1. Identify relationships between diabetes (DM) and hypertension (HTN) in the population of African American females with schizophrenia or schizoaffective disorder.  Hypotheses: 1.  There will be a significant relationship between the type of antipsychotic (traditional or atypical) and whether an African American (AA) female with schizophrenia (SCZ) or schizoaffective disorder (SZA) is on a medication for DM. 2.  There will be a significant relationship between the type of antipsychotic and whether an AA female with schizophrenia or schizoaffective disorder is on a medication for HTN.  Background: Individuals with SCZ or SZA are known to be at high risk for obesity, diabetes, and cardiovascular diseases.  African American women have a higher incidence of diabetes and cardiovascular disease, but substantial epidemiological studies of incidence rates are lacking.  There is no data available about the incidence of diabetes and cardiovascular diseases in AA females with schizophrenia, despite the increased risk in the general population.  Research identifying risk factors and relationships between schizophrenia, obesity, diabetes, cardiovascular disease, ethnicity, and traditional versus atypical antipsychotic drug treatment is needed so that psychiatric nurse practitioners (PMHNP) can make more informed decisions as to drug treatment choice and can develop targeted prevention strategies for this population. Method: An exploratory design using retrospective chart data was used in this study to gain insight into epidemiological data and possible risk factors for diabetes and cardiovascular diseases in the AA female population with a psychotic disorder.  A de-identified list of medical records of AA females with SCZ or SZA between the ages of 21-50 years was obtained from a large urban public mental health system.  A random list of 400 records was derived from that list and was involved in this retrospective chart review.  Institutional Review Board and Agency approval were obtained and no identifying information was included in the data collection. Data collected included:  age, family history of diabetes and cardiovascular disease, height, weight, vital signs, body mass index (BMI), glucose and lipid levels, type of antipsychotic medication, and use of medication to treat diabetes, hypertension, and cardiovascular disease. Results: A large number of data points was missing from many of the random medical records.  A sample of 135 cases that met inclusion criteria was included in the final analysis. Logistic regression (LR) analysis of categorical data of the type of antipsychotic medication and the use of medication for DM or HTN was performed.  The LR both without and with BMI did not show any significant association between type of antipsychotic drug and use of drug for diabetes or HTN.  Chi square tests of association (Fisher's exact test) were also not significant. Implications: This study was the first step in identifying risk factors for and predictors of cardiovascular diseases and diabetes in AA females with a psychotic disorder.  The PMHNP needs to continue to conduct research in this high risk group to better design and implement more appropriate prevention and treatment programs.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Western Institute of Nursing

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleDiabetes, Hypertension and African American Females With Schizophreniaen_GB
dc.identifier.urihttp://hdl.handle.net/10755/157670-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Diabetes, Hypertension and African American Females With Schizophrenia</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Western Institute of Nursing</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2009</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Weber, Mary T., PhD, APRN, PMHNP-BC</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of Colorado Denver, College of Nursing</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Associate Professor</td></tr><tr class="item-address"><td class="label">Contact Address:</td><td class="value">13120 East 19th Ave. C288-18; Room 4234, Aurora, CO, 80045, USA</td></tr><tr class="item-phone"><td class="label">Contact Telephone:</td><td class="value">303-724-2949</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">Mary.Weber@UCDenver.edu</td></tr><tr><td colspan="2" class="item-abstract">Aim: 1. Identify relationships between diabetes (DM) and hypertension (HTN) in the population of African American females with schizophrenia or schizoaffective disorder.&nbsp; Hypotheses: 1.&nbsp; There will be a significant relationship between the type of antipsychotic (traditional or atypical) and whether an African American (AA) female with schizophrenia (SCZ) or schizoaffective disorder (SZA) is on a medication for DM. 2.&nbsp; There will be a significant relationship between the type of antipsychotic and whether an AA female with schizophrenia or schizoaffective disorder is on a medication for HTN.&nbsp; Background: Individuals with SCZ or SZA are known to be at high risk for obesity, diabetes, and cardiovascular diseases. &nbsp;African American women have a higher incidence of diabetes and cardiovascular disease, but substantial epidemiological studies of incidence rates are lacking.&nbsp; There is no data available about the incidence of diabetes and cardiovascular diseases in AA females with schizophrenia, despite the increased risk in the general population.&nbsp; Research identifying risk factors and relationships between schizophrenia, obesity, diabetes, cardiovascular disease, ethnicity, and traditional versus atypical antipsychotic drug treatment is needed so that psychiatric nurse practitioners (PMHNP) can make more informed decisions as to drug treatment choice and can develop targeted prevention strategies for this population. Method: An exploratory design using retrospective chart data was used in this study to gain insight into epidemiological data and possible risk factors for diabetes and cardiovascular diseases in the AA female population with a psychotic disorder.&nbsp; A de-identified list of medical records of AA females with SCZ or SZA between the ages of 21-50 years was obtained from a large urban public mental health system.&nbsp; A random list of 400 records was derived from that list and was involved in this retrospective chart review.&nbsp; Institutional Review Board and Agency approval were obtained and no identifying information was included in the data collection. Data collected included:&nbsp; age, family history of diabetes and cardiovascular disease, height, weight, vital signs, body mass index (BMI), glucose and lipid levels, type of antipsychotic medication, and use of medication to treat diabetes, hypertension, and cardiovascular disease.&nbsp;Results:&nbsp;A large number of data points was missing from many of the random medical records.&nbsp; A sample of 135 cases that met inclusion criteria was included in the final analysis. Logistic regression (LR) analysis of categorical data of the type of antipsychotic medication and the use of medication for DM or HTN was performed.&nbsp; The LR both without and with BMI did not show any significant association between type of antipsychotic drug and use of drug for diabetes or HTN.&nbsp; Chi square tests of association (Fisher's exact test) were also not significant.&nbsp;Implications: This study was the first step in identifying risk factors for and predictors of cardiovascular diseases and diabetes in AA females with a psychotic disorder.&nbsp; The PMHNP needs to continue to conduct research in this high risk group to better design and implement more appropriate prevention and treatment programs.</td></tr></table>en_GB
dc.date.available2011-10-26T20:05:32Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T20:05:32Z-
dc.description.sponsorshipWestern Institute of Nursingen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.